Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01334 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Zhi Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, A…. Hauptthemen laut MEDLINE: Phosphoglycerate Kinase, Inflammatory Bowel Diseases, Purines, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Hefei Institutes of Physical Science, Chinese Academy of Sciences, Major Science and Technology Projects in Anhui Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Phosphoglycerate kinase 1 (PGK1) has garnered increasing attention as a potential therapeutic target for inflammatory bowel disease (IBD). Current PGK1 inhibitors face limitations in potency and pharmacokinetics, necessitating improved agents. Herein, we report the structure-guided rational optimization of purine derivatives, leading to the identification of 6e, a potent and selective PGK1 inhibitor featuring a novel scaffold. Notably, 6e exhibits remarkable selectivity across 210 protein kinases and favorable pharmacokinetic profiles in rodents. In vitro, 6e inhibits PGK1-mediated glycolytic metabolism and reduces glucose consumption/lactate production. Mechanistic studies revealed that 6e enhances Nrf2 accumulation and HO-1 expression and suppresses the transcription and protein levels of the inflammatory cytokines IL-1β and IL-6. In vivo, 6e effectively ameliorates colon shortening and histopathology in dextran sulfate sodium (DSS)-induced experimental colitis in mice. Collectively, this study provides a therapeutically promising lead compound for targeting PGK1 in IBD while also serving as a valuable tool for investigating PGK1 mechanisms in diverse diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, P. R. China.
- University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.
- Precision Cancer Medicine Engineering Research Center of Anhui Province, Hefei, Anhui 230088, P. R. China.
- Primary Cell Engineering Joint Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China.
ORCID-Profile: Jing Liu, Qingsong Liu
Förderung
- Hefei Institutes of Physical Science, Chinese Academy of Sciences
- Major Science and Technology Projects in Anhui Province
- National Natural Science Foundation of China
- Anhui Provincial Key Research and Development Plan
Zitieren
APA
Huang, Z., Ge, J., Chen, Y., Zou, F., Liu, Q., Wang, B., Zhou, Y., Wu, C., Wang, W., Wang, A., Liu, J., & Liu, Q. (2025). Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01334
Vancouver
Huang Z, Ge J, Chen Y, Zou F, Liu Q, Wang B, et al. Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01334
BibTeX
@article{Huang2025,
author = {Huang, Zhi and Ge, Juan and Chen, Yongfei and Zou, Fengming and Liu, Qingwang and Wang, Beilei and Zhou, Yangguo and Wu, Chao and Wang, Wenchao and Wang, Aoli and Liu, Jing and Liu, Qingsong},
title = {Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01334}
}
EUVIMED